Pharmacokinetic correlation of structurally modified chalcone derivatives as promising leads to treat tuberculosis
In this study, we evaluated the potential of curated structurally modified chalcone derivatives as anti-tuberculosis (TB) agents through computer-aided drug design. Compounds from the flavonoid family known as chalcones were identified by the chemical group 1,3-diaryl-2-propen-1-one. After a search of the literature, 14 outstanding structurally modified chalcones were selected and evaluated for inhibitory activity against Mycobacterium tuberculosis H37Rv targets. The therapeutic potential of the chalcones was directly based on the drug-likeness and pharmacokinetic properties of the synthesized compounds. Prompt drug selection and personalized therapy are required to prevent TB from progressing and spreading to others. Pharmacokinetic parameters helps in the identification of lead molecule, at the earlier stages of drug development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 15(2023), 20 vom: 25. Okt., Seite 1903-1913 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sabarathinam, Sarvesh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5S5A2Q39HX |
|---|
| Anmerkungen: |
Date Completed 07.11.2023 Date Revised 13.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2023-0161 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363694889 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363694889 | ||
| 003 | DE-627 | ||
| 005 | 20231226093910.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2023-0161 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1212.xml |
| 035 | |a (DE-627)NLM363694889 | ||
| 035 | |a (NLM)37877262 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sabarathinam, Sarvesh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacokinetic correlation of structurally modified chalcone derivatives as promising leads to treat tuberculosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.11.2023 | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In this study, we evaluated the potential of curated structurally modified chalcone derivatives as anti-tuberculosis (TB) agents through computer-aided drug design. Compounds from the flavonoid family known as chalcones were identified by the chemical group 1,3-diaryl-2-propen-1-one. After a search of the literature, 14 outstanding structurally modified chalcones were selected and evaluated for inhibitory activity against Mycobacterium tuberculosis H37Rv targets. The therapeutic potential of the chalcones was directly based on the drug-likeness and pharmacokinetic properties of the synthesized compounds. Prompt drug selection and personalized therapy are required to prevent TB from progressing and spreading to others. Pharmacokinetic parameters helps in the identification of lead molecule, at the earlier stages of drug development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a TB | |
| 650 | 4 | |a chalcone | |
| 650 | 4 | |a drug discovery | |
| 650 | 4 | |a metabolism | |
| 650 | 4 | |a pharmacokinetic parameters | |
| 650 | 7 | |a Chalcone |2 NLM | |
| 650 | 7 | |a 5S5A2Q39HX |2 NLM | |
| 650 | 7 | |a Chalcones |2 NLM | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 700 | 1 | |a Ganamurali, Nila |e verfasserin |4 aut | |
| 700 | 1 | |a Satheesh, Sanjana |e verfasserin |4 aut | |
| 700 | 1 | |a Dhanasekaran, Dhivya |e verfasserin |4 aut | |
| 700 | 1 | |a Raja, Arun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 15(2023), 20 vom: 25. Okt., Seite 1903-1913 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:20 |g day:25 |g month:10 |g pages:1903-1913 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2023-0161 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 20 |b 25 |c 10 |h 1903-1913 | ||